• 1. Alumina grafted SBA-15 sustainable bifunctional catalysts for direct cross-coupling of benzylic alcohols to diarylmethanes?
  Chandran Rajendran,Govindaswamy Satishkumar,Charlotte Lang,Eric M. Gaigneaux Catal. Sci. Technol., 2020,10, 2583-2592
• 2. An aquatic host–guest complex between a supramolecular G-quadruplex and the anticancer drug doxorubicin?
  José M. Rivera,Mariana Martín-Hidalgo,Jean C. Rivera-Ríos Org. Biomol. Chem., 2012,10, 7562-7565
• 3. An insight into the hybridization mechanism of hairpin DNA physically immobilized on chemically modified graphenes
  Adeline Huiling Loo,Alessandra Bonanni,Martin Pumera Analyst, 2013,138, 467-471
• 4. Alternative donor substrates for inverting and retaining glycosyltransferases?
  Luke L. Lairson,Warren W. Wakarchuk Chem. Commun., 2007, 365-367
• 5. An atomistic mechanism for the degradation of perovskite solar cells by trapped charge?
  Eunhak Lim,Jiyoung Heo,Seong Keun Kim Nanoscale, 2019,11, 11369-11378

Introduction to 2-(Methylsulfonyl)-4,6-diphenylpyrimidine (CAS No. 958727-25-8)

2-(Methylsulfonyl)-4,6-diphenylpyrimidine, identified by the Chemical Abstracts Service Number (CAS No.) 958727-25-8, is a specialized organic compound that has garnered significant attention in the field of pharmaceutical chemistry and medicinal biology. This compound belongs to the pyrimidine class, a heterocyclic aromatic structure that is widely recognized for its biological activity and pharmacological potential. The presence of a methylsulfonyl group at the 2-position and two phenyl rings at the 4 and 6 positions introduces unique electronic and steric properties, making it a valuable scaffold for drug discovery and development.

The methylsulfonyl moiety, characterized by its electron-withdrawing nature, plays a crucial role in modulating the reactivity and binding affinity of the molecule. This functional group has been extensively studied for its ability to enhance metabolic stability and improve pharmacokinetic profiles in drug candidates. In contrast, the phenyl rings contribute to hydrophobic interactions and can be further modified to fine-tune solubility and bioavailability. The combination of these structural features makes 2-(Methylsulfonyl)-4,6-diphenylpyrimidine a promising candidate for various therapeutic applications.

Recent advancements in computational chemistry and molecular modeling have enabled researchers to predict the biological activity of this compound with greater precision. Studies suggest that the methylsulfonyl group may interact with specific enzymatic targets, potentially inhibiting key pathways involved in inflammation, cancer, and neurodegenerative diseases. The phenyl rings, on the other hand, can be engineered to enhance binding affinity through π-stacking interactions or other non-covalent forces. These insights have guided the design of derivatives with improved efficacy and reduced side effects.

In vitro experiments have demonstrated that 2-(Methylsulfonyl)-4,6-diphenylpyrimidine exhibits notable activity against certain cancer cell lines. The compound has been shown to disrupt microtubule formation and induce apoptosis in tumor cells, making it a potential candidate for anticancer therapy. Additionally, preliminary studies indicate that it may possess anti-inflammatory properties by modulating cytokine production and inhibiting inflammatory signaling pathways. These findings highlight the compound's therapeutic potential and justify further investigation into its mechanisms of action.

The synthesis of 2-(Methylsulfonyl)-4,6-diphenylpyrimidine involves multi-step organic reactions that require precise control over reaction conditions and reagent selection. Advanced synthetic methodologies, such as transition metal-catalyzed cross-coupling reactions, have been employed to achieve high yields and purity. The development of efficient synthetic routes is essential for scaling up production and conducting comprehensive biological evaluations. Collaborative efforts between synthetic chemists and biologists have accelerated the discovery process by integrating structural optimization with functional assays.

One of the most compelling aspects of 2-(Methylsulfonyl)-4,6-diphenylpyrimidine is its versatility as a pharmacophore. By modifying specific atoms or functional groups within its structure, researchers can generate libraries of derivatives with tailored biological activities. This approach has been successfully applied in high-throughput screening campaigns to identify novel lead compounds for drug development. The compound's well-defined scaffold provides a robust platform for exploring new therapeutic strategies across multiple disease areas.

The pharmacokinetic profile of 2-(Methylsulfonyl)-4,6-diphenylpyrimidine is another critical factor that influences its clinical potential. Preclinical studies have shown that it exhibits favorable absorption, distribution, metabolism, and excretion (ADME) properties when administered orally or intravenously. These findings are supported by computational simulations that predict optimal dosing regimens and route of administration based on physicochemical properties such as solubility and permeability. Such data are invaluable for guiding clinical trial design and optimizing therapeutic outcomes.

Regulatory considerations also play a significant role in advancing 2-(Methylsulfonyl)-4,6-diphenylpyrimidine towards clinical application. Compliance with Good Manufacturing Practices (GMP) ensures that synthesized batches meet stringent quality standards required for human testing. Additionally, rigorous toxicological assessments are conducted to evaluate safety margins and potential adverse effects before proceeding to Phase I clinical trials. These regulatory milestones are essential for ensuring patient safety while maximizing therapeutic benefits.

The future prospects of 2-(Methylsulfonyl)-4,6-diphenylpyrimidine are promising given its unique structural features and demonstrated biological activity. Ongoing research aims to elucidate its mechanism of action at a molecular level through techniques such as X-ray crystallography and nuclear magnetic resonance (NMR) spectroscopy. Such structural insights will inform rational drug design efforts aimed at improving potency while minimizing off-target effects.

Collaborative initiatives between academic institutions, pharmaceutical companies, and biotech firms are fostering innovation in this field by pooling resources and expertise. These partnerships accelerate translation from bench to bedside by streamlining preclinical development processes. As new technologies emerge in areas such as artificial intelligence-driven drug discovery platforms, 2-(Methylsulfonyl)-4, 6-diphenylpyrimidine may benefit from enhanced computational tools that predict molecular interactions with unprecedented accuracy.

• 75175-89-2(Pyrimidine, 2-(methylsulfonyl)-4-[3-(trifluoromethyl)phenyl]-)
• 89079-63-0(5-Pyrimidinecarbonitrile, 2-(methylsulfonyl)-4-phenyl-)
• 1027064-22-7(4-(4-Bromophenyl)-2-(methylsulfonyl)pyrimidine)
• 56734-11-3(2-Methanesulfonyl-4-phenyl-pyrimidine)
• 16879-59-7(Pyrimidine, 2,2'-thiobis[4-methyl-6-phenyl-)
• 35144-22-0(2-methanesulfonyl-4,6-dimethylpyrimidine)
• 637354-25-7(Pyrimidine, 2-(methylsulfonyl)-4-(3-pyridinyl)-)
• 434941-56-7(4-(4-Chlorophenyl)-2-(methylsulfonyl)pyrimidine)
• 56734-10-2(2-(Methylthio)-4-phenylpyrimidine)
• 77166-01-9(4-Methyl-2-(methylsulfonyl)pyrimidine)